簡(jiǎn)要描述:磷酸化心臟磷蛋白(Ser16+Thr17)抗體免 疫 原;KLH conjugated synthesised phosphopeptide derived from human PLB around the phosphorylation site of Ser16+Thr17: RA(p-S)(p-T)IE
產(chǎn)品分類(lèi)
Product Category相關(guān)文章
Related Articles詳細(xì)介紹
磷酸化心臟磷蛋白(Ser16+Thr17)抗體
產(chǎn)品名稱(chēng) | 英文名稱(chēng) | 貨號(hào) |
磷酸化心臟磷蛋白(Ser16+Thr17)抗體 | phospho-PLB (Ser16+Thr17) | GOY-01K1936 |
商品屬性:
英文名稱(chēng): phospho-PLB (Ser16+Thr17)
中文名:磷酸化心臟磷蛋白(Ser16+Thr17)抗體
別 名;Phospholamban
(phospho S16+T17); p-Phospholamban (phospho S16+T17); Phospho-Phospholamban
(Ser16/Thr17); phospholamban(phospho Ser16+Thr17); p-PLB(S16+T17); Cardiac
phospholamban; CMD1P; PLB; PLN; PPLA_HUMAN.
研究領(lǐng)域;心血管 免疫學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 轉(zhuǎn)錄調(diào)節(jié)因子 通道蛋白
抗體來(lái)源;Rabbit
克隆類(lèi)型;Polyclonal
交叉反應(yīng);(predicted:
Human, Mouse, Rat, Dog, Pig, Cow, Sheep, )
產(chǎn)品應(yīng)用;WB=1:500-2000
ELISA=1:5000-10000
not yet tested in
other applications.
optimal
dilutions/concentrations should be determined by the end user.
理論分子量;6kDa
細(xì)胞定位;細(xì)胞漿 細(xì)胞膜
性 狀;Liquid
濃 度;1mg/ml
免 疫 原;KLH
conjugated synthesised phosphopeptide derived from human PLB around the
phosphorylation site of Ser16+Thr17: RA(p-S)(p-T)IE
亞 型;IgG
純化方法;affinity
purified by Protein A
緩 沖 液;Preservative:
15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
注意事項(xiàng);This
product as supplied is intended for research use only, not for use in human,
therapeutic or diagnostic applications.
產(chǎn)品介紹:
The protein encoded by this gene is found as a
pentamer and is a major substrate for the cAMP-dependent protein kinase in
cardiac muscle. The encoded protein is an inhibitor of cardiac muscle
sarcoplasmic reticulum Ca(2+)-ATPase in the unphosphorylated state, but
inhibition is relieved upon phosphorylation of the protein. The subsequent
activation of the Ca(2+) pump leads to enhanced muscle relaxation rates,
thereby contributing to the inotropic response elicited in heart by
beta-agonists. The encoded protein is a key regulator of cardiac diastolic
function. Mutations in this gene are a cause of inherited human dilated
cardiomyopathy with refractory congestive heart failure. [provided by RefSeq,
Jul 2008]. Phospholamban has been postulated to regulate the
activity of the calcium pump of cardiac sarcoplasmic reticulum. |
多克隆抗體制備:
我公司合成抗原,保證陽(yáng)性血清和抗體ELISA效價(jià)達(dá)到1:32000,由蛋白抗原制備的多抗,保證WB檢測(cè)結(jié)果是陽(yáng)性。技術(shù)服務(wù)實(shí)行分步報(bào)價(jià),按節(jié)點(diǎn)收費(fèi),為客戶(hù)節(jié)約成本。
鼠單克隆抗體制備:
客戶(hù)可根據(jù)項(xiàng)目實(shí)際需求情況靈活選擇進(jìn)行,我公司將為您的項(xiàng)目提供專(zhuān)業(yè)的建議。在制備過(guò)程中,與客戶(hù)互動(dòng)驗(yàn)證,確保最終制備的抗體ELISA陽(yáng)性血清檢測(cè)達(dá)到合同要求的同時(shí),也能滿(mǎn)足客戶(hù)抗體最終應(yīng)用驗(yàn)證需求。技術(shù)服務(wù)實(shí)行分步報(bào)價(jià),按節(jié)點(diǎn)收費(fèi),為客戶(hù)節(jié)約成本。
重組抗體表達(dá)服務(wù):
重組抗體技術(shù)使制備人源化抗體和人源抗體成為可能,而這是其他常規(guī)的多克隆或單克隆抗體制備方法無(wú)法做到的。我公司已搭建好的抗體測(cè)序、重組抗體表達(dá)等先進(jìn)平臺(tái),能為客戶(hù)提供各種類(lèi)型的重組抗體表達(dá)服務(wù),包含鼠源單克隆抗體構(gòu)建及表達(dá)、更換恒定區(qū)亞型的嵌合抗體表達(dá),抗體人源化改造及表達(dá)等服務(wù)。
單項(xiàng)免疫學(xué)及檢測(cè)服務(wù):
我公司也為客戶(hù)提供單項(xiàng)免疫學(xué)和檢測(cè)服務(wù),如動(dòng)物免疫、動(dòng)物飼養(yǎng)、抗體修飾服務(wù)(如FITC,HRP等的標(biāo)記)、以及ELISA,WB,IHC,DB等檢測(cè)服務(wù)。
抗體定制服務(wù):
已注冊(cè)商標(biāo),主要用于抗體藥物發(fā)現(xiàn)和開(kāi)發(fā),是我公司針對(duì)有特定應(yīng)用要求和各種模型測(cè)試的客戶(hù)量身定制的專(zhuān)業(yè)服務(wù),主要面向工業(yè)客戶(hù)。
產(chǎn)品咨詢(xún)
歡迎您關(guān)注我們的微信了解更多信息
電話
微信掃一掃